Filling the Analysis Gap in the Move to Continuous Processing

The author discusses issues and best approaches for solid dosage form pharmaceuticals.

More pharmaceutical companies are becoming interested in continuous processing, but they may face an “analytics gap,” because continuous will require a different approach to analytics. The author discusses issues and best approaches for solid dosage form pharmaceuticals.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.

Articles in this issue

about 10 years ago

Article

Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry

about 10 years ago

Article

Optimizing Tablet Compression

about 10 years ago

Article

Excipient Quality and Selection

about 10 years ago

Article

Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

about 10 years ago

Article

Modeling and Simulation Move Downstream

about 10 years ago

Article

Unifying Excipient Databases

about 10 years ago

Article

Establishing a New Performance Standard for HPMC Capsules

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.